Pediatric Acute Lymphoblastic Leukemia

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

This book discusses key aspects of childhood acute lymphoblastic leukemia (ALL), presenting the latest research on the biology and treatment of the disease and related issues. The cure rate for ALL has improved dramatically due to advances such as supportive care, treatment stratification based on relapse risk, and the optimization of treatment regimens. Gathering contributions by eminent scholars Pediatric Acute Lymphoblastic Leukemia is a valuable resource for pediatric hematologists as well as for medical students, interns, residents and fellows. It not only offers comprehensive insights, but also provides a springboard for future research.

This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills.

During the last few decades, there has been a tremendous improvement in the treatment of cancer. There is evidence that this trend is continuing, based on the achievements re sulting from the combined efforts of clinicians and basic re search workers. This book is an example of such interaction and collaboration. It was prepared by authors representing both areas of work. Most of the work reported in this book is not merely theoretical, but has been experimentally successfully tested and sometimes applied clinically. This work has, however, not yet been generalized and practiced on a wide scale. Some of the results reported here relate to new aspects and open new horizons for future progress. This book will be of great value for both clinicians and basic research workers. VICC Treatment and Rehabilitation Programme ISMAIL ELSEBAI Chairman Preface The three main approaches to the treatment of cancer are surgery, radiotherapy, and chemotherapy. Today, all malignant neoplasms are managed by one or more of these modalities, with varying success rates depending on the type of tumor, its degree of spread, and the knowl edge and skill with which the treatment plan has been designed and executed. In the United States of America and in Europe, approximate ly half of all cancer is presently curable, but this has been the case for approximately 20 years.

The book Advances in Hematologic Malignancies presents new knowledge of cellular disease processes, molecular pathology, and cytogenetic, epigenetic, and genomic changes that have influenced the current outlook toward hematological malignancies. This book provides a unique, practical, and concise guide that is focused on the must-know points of diagnosis, prognosis, therapeutic management, and cutting edge clinical trial opportunities for each hematologic malignancy. Advances in Hematologic Malignancies is designed and organized as an essential reference source for the hematologist, hematologic oncologist, hematopathologist, and trainee.

This book describes different perspectives of childhood acute lymphoblastic leukemia. The approach includes aspects of molecular epidemiology, particularly molecular features that influence the genesis and prognosis of the disease. Some aspects of the prognosis of lymphoblastic leukemias are very detailed, highlighting the use of molecular biology in the early identification of complications that may occur in diseased patients. The authors of the present book conform a Mexican group who identifies the causes of leukemia, and they summarize their experience in research, results and proposals for future studies. A causal model is included in which the authors hypothesized the origin of acute lymphoblastic leukemias, particularly in children. This hypothesis can be useful to better understand other cancers during childhood. This book will help the reader to identify different molecular aspects involved in leukemia, and its relation to the development and evolution of the disease.

This book discusses key aspects of childhood acute lymphoblastic leukemia (ALL), presenting the latest research on the biology and treatment of the disease and related issues. The cure rate for ALL has improved dramatically due to advances such as supportive care, treatment stratification based on relapse risk, and the optimization of treatment regimens. Gathering contributions by eminent scholars Pediatric Acute Lymphoblastic Leukemia is a valuable resource for pediatric hematologists as well as for medical students, interns, residents and fellows. It not only offers comprehensive insights, but also provides a springboard for future research.